Pfizer beat consensus exp. in the Mrch period. The EPS for 2016 are 1.72/1.85 $, on sales of 51/53 billion $. We think that the split between the core human pharma and the rest of the Group probably could come in late 2016. Strong financial position.
交易结束：到达目标
⋅
评论
mgiuliani
⋅
On 14th July the target was reached
649bruno
⋅
Pfizer was weaker earlier this year, but its price action has been in a solid uptrend since the beginning of April. You have constructed a very good chart and analysis, and I certainly do agree with your bullish view. Don.
mgiuliani
⋅
Thank you Sir, for your appreciation.
Regards
mgiuliani
⋅
IMPORTANT:
Please remind yourself that this is just my personal view on the market. My analysis should NOT serve as any recommendation to buy or to sell.
If you find useful my analysis, please hit the LIKE button and follow me.